🚨 Bioverge Access Fund 4 is now accepting investors! Leverage Bioverge expertise and back 15 leading healthcare startups through a single investment. Learn more and invest
Rxc4yp9nt6qcuepqtubv

The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

continue reading >
Xzq3odngqhq7wbfon459

The Bioverge Podcast: Investing in the Bio-Based Future

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

continue reading >
O9b1fx9rqw20zjgd7p0r

The Bioverge Podcast: From Bugs to Drugs

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

continue reading >
Dbptgytqynpkrxowc9ja

The Bioverge Podcast: Curing Blindness with Cell Therapy

On this episode, Arnaud Lacoste, chief scientific officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

continue reading >
24vhjycnqkurcd9ev2pb

The Bioverge Podcast: A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

continue reading >
Ty3n7b6qtc6dkvq2dcwt

The Bioverge Podcast: Accelerating Timelines and The Bioverge Podcast: Improving Outcomes with a Predictive Precision Medicine Platform

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

continue reading >
Vb4znhl4qaeqarhtmzyt

The Bioverge Podcast: Changing Drug Discovery with Transomics

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

continue reading >
Ayk8vtkvt5ccqioayxrx

The Bioverge Podcast: Engineering Intelligence into Cell and Gene Therapies

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

continue reading >
Gn0b1g1stpyzwlejguor

The Bioverge Podcast: Addressing the Challenges of Chronic Liver Disease

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

continue reading >
1uznqvqosdativrqevym

Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M

Congratulations to the Volumetric team on their acquisition by 3D Systems!

continue reading >
Rxc4yp9nt6qcuepqtubv
Media

The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Continue Reading >
Xzq3odngqhq7wbfon459
Media

The Bioverge Podcast: Investing in the Bio-Based Future

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

Continue Reading >
O9b1fx9rqw20zjgd7p0r
Media

The Bioverge Podcast: From Bugs to Drugs

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

Continue Reading >
Dbptgytqynpkrxowc9ja
Media

The Bioverge Podcast: Curing Blindness with Cell Therapy

On this episode, Arnaud Lacoste, chief scientific officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

Continue Reading >
24vhjycnqkurcd9ev2pb
Media

The Bioverge Podcast: A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

Continue Reading >
Ty3n7b6qtc6dkvq2dcwt
Media

The Bioverge Podcast: Accelerating Timelines and The Bioverge Podcast: Improving Outcomes with a Predictive Precision Medicine Platform

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

Continue Reading >
Vb4znhl4qaeqarhtmzyt
Media

The Bioverge Podcast: Changing Drug Discovery with Transomics

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

Continue Reading >
Ayk8vtkvt5ccqioayxrx
Media

The Bioverge Podcast: Engineering Intelligence into Cell and Gene Therapies

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

Continue Reading >
Gn0b1g1stpyzwlejguor
Media

The Bioverge Podcast: Addressing the Challenges of Chronic Liver Disease

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

Continue Reading >
1uznqvqosdativrqevym
Health + Tech, Investing, Startups

Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M

Congratulations to the Volumetric team on their acquisition by 3D Systems!

Continue Reading >
Next